Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii

• Status: Unknown status
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Compare the clinical efficiency evaluated by the treatment of the intravenous colistin plus inhaled colistin opposite to the treatment with colistin intravenous plus inhaled saline solution in patients with VAP due to baumannii carbapenems resistant.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospitales Universitarios Virgen del Rocío
• Treatments: Colistin; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Diagnose of VAP due A. baumannii or A. baumannii and another microorganism carbapenems resistant.

• Clinical Pulmonary Infection Score (CPIS) > 6

Exclusion Criteria:

• Allergy to colistin.

• Asthma

• Shock status

• Diagnose of VAP due A. baumannii colistin resistant.